Compare ABVC & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVC | MYO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 36.9M |
| IPO Year | 2009 | 2017 |
| Metric | ABVC | MYO |
|---|---|---|
| Price | $1.05 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 151.7K | ★ 291.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $509,589.00 | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.88 | $0.61 |
| 52 Week High | $4.02 | $4.99 |
| Indicator | ABVC | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 56.57 |
| Support Level | $0.88 | $0.80 |
| Resistance Level | $1.71 | $0.85 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 7.14 | 54.75 |
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).